Remdesivir for the Treatment of Covid-19 — Preliminary Report
Top Cited Papers
- 3 September 2020
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (10), 992-994
- https://doi.org/10.1056/nejmc2022236
Abstract
We would like to direct attention to the enrollment criteria in the trial described in the article by Beigel et al. (published online on May 22 at NEJM.org).1 In patients with Covid-19–related respiratory disease, these criteria resulted in the use of remdesivir well into the illness. The median time from symptom onset to randomization was 9 days.This publication has 15 references indexed in Scilit:
- Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular StudiesCirculation, 2019
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal InfluenzaaClinical Infectious Diseases, 2019
- Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival TimeThe American Journal of Medicine, 2019
- Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing RisksJAMA Cardiology, 2018
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard RatioJAMA Oncology, 2017
- Surviving Sepsis GuidelinesJAMA, 2017
- Time to first antibiotic and mortality in adults hospitalised with community-acquired pneumonia: a matched-propensity analysisThorax, 2015
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000
- Double-blind Placebo-Controlled Trial of Oral Acyclovir in First-Episode Genital Herpes Simplex Virus InfectionJAMA, 1984